FRED HUTCHINSON CANCER CENTER
🇺🇸United States
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Phase 1
Suspended
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeRecurrent Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRefractory Mixed Phenotype Acute LeukemiaAcute Myeloid Leukemia in RemissionRecurrent Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia in RemissionMyelodysplastic Syndrome With Excess BlastsChronic Myelomonocytic LeukemiaRefractory Acute Lymphoblastic Leukemia
- Interventions
- Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10Drug: CyclophosphamideRadiation: Total-Body IrradiationProcedure: Peripheral Blood Stem Cell TransplantationProcedure: Bone Marrow TransplantationDrug: Mycophenolate MofetilBiological: Recombinant Granulocyte Colony-Stimulating FactorDrug: Fludarabine PhosphateDrug: TacrolimusProcedure: Bone Marrow Aspiration and BiopsyProcedure: Biospecimen Collection
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT03670966
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
Phase 1
Terminated
- Conditions
- Metastatic LeiomyosarcomaMetastatic Undifferentiated Pleomorphic SarcomaRefractory Undifferentiated Pleomorphic SarcomaAdvanced Synovial SarcomaAdvanced Undifferentiated Pleomorphic SarcomaAdvanced LeiomyosarcomaMetastatic Synovial SarcomaRefractory LeiomyosarcomaRefractory Round Cell LiposarcomaRefractory Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT03670069
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
Phase 2
Withdrawn
- Conditions
- Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromeMyelofibrosisRecurrent Hodgkin LymphomaTherapy-Related Acute Myeloid LeukemiaChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveHematopoietic and Lymphoid System NeoplasmAcute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeRecurrent Non-Hodgkin Lymphoma
- Interventions
- Biological: Anti-Thymocyte GlobulinDrug: BusulfanDrug: CyclophosphamideDrug: CyclosporineDrug: Fludarabine PhosphateDrug: MethotrexateProcedure: Peripheral Blood Stem Cell TransplantationOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationDrug: TacrolimusRadiation: Total-Body Irradiation
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT03602898
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Smoking Cessation Smartphone App for Cancer Patients (Quit2Heal Study)
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 59
- Registration Number
- NCT03600038
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Pilot Trial of the First Conversational Agent for Smoking Cessation (QuitBot)
- First Posted Date
- 2018-07-12
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 404
- Registration Number
- NCT03585231
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
SmART Heart: Study of mHealth Apps to Reduce Cancer-Treatment Effects on the Heart
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 41
- Registration Number
- NCT03574012
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 66
- Registration Number
- NCT03531918
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Positive Psychology Intervention to Improve Quality of Life in Stem Cell Transplant Survivors and Their Caregivers
- First Posted Date
- 2018-05-15
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT03525106
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors
Not Applicable
Completed
- Conditions
- Anatomic Stage IIA Breast Cancer AJCC v8Cancer SurvivorPrognostic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8HER2/Neu NegativeAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Progesterone Receptor PositivePrognostic Stage II Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT03523195
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer
Phase 1
Completed
- Conditions
- Anatomic Stage IIIC Breast Cancer AJCC v8Invasive Breast CarcinomaPrognostic Stage IIB Breast Cancer AJCC v8Breast Cancer FemaleAnatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT03518242
- Locations
- 🇺🇬
Uganda Cancer Institute, Kampala, Uganda
🇺🇬New Mulago Hospital, Kampala, Uganda
© Copyright 2024. All Rights Reserved by MedPath